ArticleThe Journal of clinical endocrinology and metabolism2025
Subtle Cognitive Impairments and Psychological Complaints in Patients With Prolactinoma Despite Biochemical Control.
Article in The Journal of clinical endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- How to Define Success in Prolactinoma Treatment-A Systematic Review and Theoretical Framework.The Journal of clinical endocrinology and metabolism · 2026Pooled it
- Subtle Cognitive Impairments and Psychological Complaints in Patients With Prolactinoma Despite Biochemical Control.The Journal of clinical endocrinology and metabolism · 2025Article
Corrections and comments
- Commented on by
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess cognitive functioning and psychological complaints in patients with biochemically controlled prolactinoma.
methodsCross-sectional study comparing otherwise healthy patients treated for prolactinoma to age-, gender-, and education level-matched controls. The cognitive assessment included 8 tests assessing memory, verbal fluency, processing speed, selective attention, and executive functioning. Additionally, patients completed 7 validated questionnaires on psychological complaints. Generalized estimating equations were performed. P values <.050 were considered significant.
resultsSixty patients (controlled on dopamine agonists, n = 30; in surgical remission, n = 30), among whom 41 (68.3%) females, aged 42.3 ± 11.7 years, were compared to 60 matched controls. Patients scored significantly lower on assessments for verbal memory (fewer words on Verbal Learning Test of Rey: β = -1.8; 95% CI, -2.7 to -1.0), selective attention (fewer correct digits on Digit Deletion Test [β = -8.8; 95% CI, -16.2 to -0.2], longer time on Trial Making Test A [β = 5.2; 95% CI, 3.2 to 7.2]), and processing speed (fewer correct substitutions on Digit-Symbol Substitution Test: β = -4.2; 95% CI, -8.2 to -0.2). Furthermore, patients reported higher degrees of apathy (Apathy Scale: β = 2.4; 95% CI, 0.6 to 4.1), irritability (Irritability Scale: β = 2.2; 95% CI, 0.3 to 4.1), fatigue (Fatigue Severity Scale: β = 6.7; 95% CI, 2.7 to 10.8), and anxiety and depressive symptoms (Hospital Anxiety and Depression Scale, anxiety: β = 1.1; 95% CI, 0.1 to 2.1; depression: β = 1.7; 95% CI, 0.8 to 2.7). Tests assessing executive functioning and task switching were comparable in patients and matched controls.
conclusionCompared to matched controls, patients with biochemically controlled prolactinoma showed subtle cognitive impairments (ie, memory, attention, and processing speed) and reported more psychological complaints. Physicians should be aware of these impairments and address them adequately.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.